Cell-Specific Inhibition of p38α as a Therapeutic Strategy for Inflammatory Bowel Disease
Authors:
- Eóin N. McNameeEMEóin N. McNamee
- Colm B. CollinsCCColm B. Collins
- Matthew D.P. LebsackMLMatthew D.P. Lebsack
- Jesús Rivera–NievesJRJesús Rivera–Nieves
Open Access
- 30 April 2010
- journal article
- editorial
- Published by Elsevier in Gastroenterology
- Vol. 138 (4) , 1237-1239
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Targeting delivery of anti-TNF oligonucleotide into activated colonic macrophages protects against experimental colitisGut, 2009
- p38 Pathway Kinases as Anti-inflammatory Drug TargetsJournal of Dental Research, 2007
- p38 MAP kinase inhibitors: many are made, but few are chosen.2005
- Interleukin-17 Family Members and InflammationImmunity, 2004
- Strong inhibition of TNF-α production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitorArthritis Research & Therapy, 2004
- p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseasesNature Reviews Drug Discovery, 2003
- p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel DiseaseThe Journal of Immunology, 2002
- Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's diseaseGastroenterology, 2002
- Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's diseaseGastroenterology, 2000
- Patterns of cell proliferation in gastrointestinal diseaseDiseases of the Colon & Rectum, 1967